Literature DB >> 12111597

Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers.

A J Matute1, C A M Schurink, R M C Krijnen, A Florijn, M Rozenberg-Arska, I M Hoepelman.   

Abstract

The purpose of this double-blind study was to assess the effect of azithromycin and clarithromycin on oral and fecal microflora. Bacterial species from fecal samples and throat washes from healthy volunteers were identified and quantified before, during and after receipt of either placebo ( n=6), azithromycin (500 mg once daily for 3 days; n=6) or clarithromycin (500 mg twice daily for 7 days; n=6). In both antibiotic groups, the changes in oropharyngeal aerobic microflora following antibiotic administration were minor. Antibiotics neither changed the bacterial load of Streptococcus spp. compared with placebo, nor did macrolide-resistant streptococci emerge. In the fecal aerobic microflora, the number of organisms of the family Enterobacteriaceae decreased slightly after antibiotic administration in both the clarithromycin and the azithromycin groups, but levels normalized by day 21 after therapy. No colonization with nonfermenters or Clostridium difficile was seen, and the total number of anaerobic bacteria was not affected in any study group. In conclusion, there were no significant differences between azithromycin and clarithromycin in their effect on human oropharyngeal and intestinal microflora, nor was the use of these antibiotics associated with colonization by resistant, gram-positive organisms or overgrowth of opportunistic microorganisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111597     DOI: 10.1007/s10096-002-0728-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children.

Authors:  Elizabeth A Gilliams; Jibreel Jumare; Cassidy W Claassen; Phillip C Thesing; Osward M Nyirenda; Fraction K Dzinjalamala; Terrie Taylor; Christopher V Plowe; LaRee A Tracy; Miriam K Laufer
Journal:  J Infect Dis       Date:  2014-03-20       Impact factor: 5.226

Review 2.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Effect of azithromycin on acute inflammatory lesions and colonic bacterial load in a murine model of experimental colitis.

Authors:  Sanja Plesko; Marko Banić; Vanda Plecko; Branimir Anić; Tomislav Brkić; Heinzl Renata; Ivo Rotkvić
Journal:  Dig Dis Sci       Date:  2009-11-19       Impact factor: 3.199

4.  Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review.

Authors:  Karen T Elvers; Victoria J Wilson; Ashley Hammond; Lorna Duncan; Alyson L Huntley; Alastair D Hay; Esther T van der Werf
Journal:  BMJ Open       Date:  2020-09-21       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.